Write the drug product manufacturing package

What should CTD P.3 show about finished-product manufacturing?

Identify the actual sites, batch formula and process, then connect critical-step controls and relevant validation or evaluation to that proposal. Reconcile the formula with P.1 and the process rationale with P.2. Show what the evidence covers by site, scale, line and version rather than describing a generic manufacturing capability.

Before you begin

M4Q(R1) P.3. Validation strategy and submission-stage expectations require the applicable product and regional assessment.

What you will prepare: A manufacturing narrative with matching material quantities, operations, controls and supporting evaluation.

P.3.1–P.3.2: identify who makes what and at which scale

For P.3.1, reconcile each manufacturing, packaging and testing responsibility with the proposed site roster, including contractors. Use names and physical addresses from controlled facility records; clarify split responsibilities rather than assigning every operation to the applicant.

For P.3.2, present the batch formula with component amounts per batch, any overages and quality-standard references. State the batch-size basis and compare it to P.1's per-unit composition. Distinguish the theoretical formula from actual yields and from development-batch variations. If multiple batch sizes or strengths are proposed, make their relationship clear and refer unsupported scaling assumptions to the manufacturing owner.

P.3.3–P.3.4: make the process traceable from entry to packaging

For P.3.3, pair a flow diagram with the actual sequence of operations and relevant equipment type/capacity, scale and parameters. Show material entry points, packaging operations and where controls occur. Give novel processes or operations affecting product quality the necessary detail. Explain proposed reprocessing with its supporting basis rather than burying it in routine instructions.

For P.3.4, list critical-step tests and criteria and explain their justification, including supporting experimental evidence. Describe isolated intermediates and how their quality is controlled. Match every critical point to the diagram and narrative. A broad operating range in one section and a narrower supported range in another is an unresolved scientific discrepancy, not an opportunity to choose the convenient value.

P.3.5: connect evaluation to the process being proposed

Describe the applicable validation/evaluation work, its scope, executed results and conclusions. Identify process version, site, scale and critical operation so the reader can tell what has been demonstrated. M4Q gives sterilization and aseptic processing/filling as examples; relevant viral safety evaluation belongs in A.2. Do not impose the same study package or completed-batch count on every process and lifecycle stage.

Fictional exercise: a sterile filling line changes after the evaluation summarized in P.3.5. Obtain the responsible validation and regulatory assessment of what the change affects. Link the evidence supporting the proposed line, or mark the coverage gap and required action. Changing only the line name in the narrative would falsely imply that the executed work covered it.

Reconcile the process proposal before writing its conclusion

For each proposed strength or batch configuration, use a working crosswalk between the formula, diagram, controls and evaluation. This is an editorial preparation tool.

Fictional review: the evaluated process used one batch size, while the dossier proposes a range. Identify the actual evidence and ask the manufacturing and validation owners what the scale relationship supports. Neither copying the historical batch size nor declaring the whole range validated resolves the scientific question.

Keep proposed future work distinguishable from completed evaluation. If a change affects a critical operation, record its dependencies before editing the narrative: development rationale, batch representativeness, stability and possibly the clinical formulation bridge.

Check P.1 composition and P.5 batch analyses after resolving the proposal. A technically correct manufacturing section can still create a dossier inconsistency if its batch or formulation identifiers differ from the supporting results.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides